Influence of the interval between preoperative radiotherapy and surgery in the treatment of rectal cancer: Commentary;Bedeutung des intervalls zwischen praoperativer radiotherapie und operation bei der behandlung des rektumkarzinoms: Kommentar

Strahlentherapie und Onkologie

Volumn 176, Issue 3, 2000, Pages 153-154

  Rödel, Claus ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; MORBIDITY; NOTE; PREOPERATIVE TREATMENT; RECTUM CANCER; ADJUVANT THERAPY; ARTICLE; CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; PREOPERATIVE CARE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTUM TUMOR; TIME; TREATMENT OUTCOME;

CARCINOMA; HUMANS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; RECTAL NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034154149     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Berger C, de Muret A, Garaud P, et al. Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. Int J Radiat Oncol Biol Phys 1997;37:619-27.
2. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396-402.
3. Junginger T, Hossfeld DK, Sauer R, et al. Adjuvante Therapie bei Kolon-und Rektumkarzinom. Dtsch Ärztebl 1999;96:A-698-700.
4. Minsky BD, Cohen AM, Kemeny N, et al. Enhancement of radiation-induced downstaging of rectal cancer by 5-FU and high-dose leucovorin chemotherapy. J Clin Oncol 1992;10:79-84.
5. Rodel C., Schick CH, Raab R, et al. Prospectively randomized trial of preoperative versus postoperative radiochemotherapy for advanced rectal cancer - first results regarding surgical morbidity and toxicity of (neo-)adjuvant treatment. Eur J Surg Oncol 1998;24:208.